Table 1 COVID-19 patients’ clinical presentation and relevant laboratory findings (N = 1337) [28, 31]
From: Clinical progression of patients with COVID-19 in Lagos State, Nigeria
Symptoms or indications that are clinically significant | |
|---|---|
Age, years | |
Median (interquartile range) | 50(35–63) |
Sex | 800(59.83%) |
Male (N, %) | |
Female (N, %) | 537(40.16%) |
Days from one set of symptoms (days) | 4(2–7) |
Admission signs and symptoms (N, %) | |
Fever | 217(16.2%) |
Cough | 211(15.78%) |
Fatigue | 36(2.69%) |
Headache and dizziness | 25(1.86%) |
Breathing problems | 15(1.12%) |
Rhinorrhoea | 19(1.42%) |
Sore throat | 18(1.34%) |
Diarrhea | 10(0.74%) |
Lack of appetence | 11(0.82%) |
Asymptomatic | 9(0.67%) |
Comorbidity (N, %) | 100(7.47%) |
Cardiovascular and cerebrovascular diseases | 66(4.93%) |
Endocrine system diseases | 35(2.61%) |
Digestive system diseases | 11(0.82%) |
Respiratory system diseases | 8(0.59%) |
Chronic hepatitis B virus infection | 4(0.29%) |
Malignant tumor | 3(0.22%) |
Laboratory findings | |
White blood cells (× 10 9 per L) | 4.71(3.80–5.86) |
Lymphocytes (× 10 9 per L) | 1.12(0.79–1.49) |
C-reactive protein (mg/L) | 12(4.4–29.4) |
Erythrocyte sedimentation rate (mm/h) | 54(33–90) |
Alanine aminotransferase (U/L) | 23(15–33) |
Aspartate aminotransferase (U/L) | 25(20–33) |
Albumin (g/L) | 40.8(37.9–43.0) |
Lactate dehydrogenase (U/L) | 229(195–291) |
Lactate (mmol/L) | 1.4(1.1–2.1) |
Estimated glomerular filtration rate (mL/min/1.73 m2) | 109.2(95.3–127.2) |
CD4 T cells counts (cells/uL) | 431(299–637) |
CD4/CD8 ratio | 1.68(1.241.33) |